RLRoy H. Lan

Roy H. Lan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Roy H. Lan has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Who are we missing? Language exclusivity of patient‐reported outcomes in atrial fibrillation clinical trials

    by Roy H. Lan, Eduardo Perez Guerrero, Eldrin F. Lewis, Paul J. Wang

    Introduction: Patient‐reported outcomes (PROs) are increasingly used to evaluate quality of life (QoL) in Atrial Fibrillation (AF) patients, providing crucial insights in clinical trials. This study examines the frequency of PRO use in AF trials and the linguistic accessibility of AF‐specific PROs.Background: As the United States becomes more multilingual, ensuring PROs are available in various languages is vital. The number of people speaking a language other than English at home has tripled from 23.1 million in 1980 to 67.8 million in 2019. This diversity necessitates the availability of PROs in multiple languages for inclusive clinical assessments.Methods: We queried ClinicalTrials.gov for all US interventional AF trials up to November 28, 2023, reviewing each for PRO usage as primary or secondary outcomes. We identified the five most common AF‐specific and generic PROs, extracting their available translations and original languages from published sources.Results: Of 233 identified trials, 191 had associated publications, with 180 (94.2%) conducted solely in English. Only one trial (0.4%) used an AF‐specific PRO as a primary outcome, compared to four (1.7%) with a generic PRO. Ten trials (4.3%) used AF‐specific PROs as secondary endpoints, versus 22 (9.4%) using generic PROs. AF‐specific PROs had significantly fewer translations than generic PROs (11.2 vs. 148.8; p < .001). The AF Effect on Quality‐of‐Life (AFEQT) was available in 24 languages, with limited translations in commonly spoken US languages like Arabic and Asian languages.Conclusion: The limited availability of AF‐specific PRO translations highlights a barrier to inclusive AF clinical trials. Expanding translations for AF‐specific PROs is crucial for equitable QoL assessments.


  • Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial

    by Alexander T. Sandhu, Jamie Calma, Megan Skye, Neil Kalwani, Jimmy Zheng, Jessica Schirmer, Natasha Din, Cati Brown Johnson, Anshal Gupta, Roy Lan, et al.

    BACKGROUND: The impact of routine clinic use of patient-reported outcome (PRO) measures on clinical outcomes in patients with heart failure (HF) has not been well-characterized. We tested if clinic-based use of a disease-specific PRO improves patient-reported quality of life at 1 year. METHODS: The PRO-HF trial (Patient-Reported Outcome Measurement in Heart Failure Clinic) was an open-label, parallel, patient-level randomized clinical trial of routine PRO assessment or usual care at an academic HF clinic between August 30, 2021, and June 30, 2022, with 1 year of follow-up. In the PRO assessment arm, participants completed the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) at each HF clinic visit, and results were shared with their treating clinician. The usual care arm completed the KCCQ-12 at randomization and 1 year later, which was not shared with the treating clinician. The primary outcome was the KCCQ-12 overall summary score (OSS) between 12 and 15 months after randomization. Secondary outcomes included domains of the KCCQ-12, hospitalization and emergency department visit rates, HF medication therapy, clinic visit frequency, and testing rates. RESULTS: Across 17 clinicians, 1248 participants were enrolled and randomized to PRO assessment (n=624) or usual care (n=624). The median age was 63.9 years (interquartile range [IQR], 51.8–72.8), 38.9% were women, and the median baseline KCCQ-12 OSS was 82.3 (IQR, 58.3–94.8). Final KCCQ-12 (available in 87.9% of the PRO arm and 85.1% in usual care; P =0.16) median OSS were 87.5 (IQR, 68.8–96.9) in the PRO arm and 87.6 (IQR, 69.7–96.9) in the usual care arm with a baseline-adjusted mean difference of 0.2 ([95% CI, −1.7 to 2.0]; P =0.85). The results were consistent across prespecified subgroups. A post hoc analysis demonstrated a significant interaction with greater benefit among participants with a baseline KCCQ-12 OSS of 60 to 80 but not in less or more symptomatic participants. No significant differences were found in 1-year mortality, hospitalizations, emergency department visits, medication therapy, clinic follow-up, or testing rates between arms. CONCLUSIONS: Routine PRO assessment in HF clinic visits did not impact patient-reported quality of life or other clinical outcomes. Alternate strategies and settings for embedding PROs into routine clinical care should be tested. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04164004.


  • Open Access

    Patient-reported outcomes in atrial fibrillation clinical trials: trends, utilisation, and implications

    by R Lan, E P G Guerrero, M S Saeed, M V P Perez

    Background/Introduction: Atrial fibrillation (AF) is the most prevalent clinical arrhythmia, and it is associated with diverse and consequential adverse outcomes that significantly impact the quality of life (QoL) experienced by patients. The evaluation and quantification of QoL have become an important aspect of assessing AF patients, with patient-reported outcomes (PROs) increasingly used in cardiovascular clinical trials. However, there is no consensus on which PROs are most suitable to report, and there is a limited understanding of their prevalence in AF clinical trials. Purpose: This study aims to characterise the utilisation of PROs in AF clinical trials. We distinguish between AF-specific and AF-agnostic PROs, with the goal of understanding the evolving role of PROs and emphasising the significance of precise measurement of patient QoL in AF research. Methods: We queried the ClinicalTrials.gov database for all available clinical trials that focused on AF as the primary condition from inception to August 1, 2023. This search yielded 3,208 clinical trials, encompassing a total of 65,545,864 participants. We filtered and manually reviewed each clinical trial for their use of PROs within the "outcomes measures" field and divided the results between AF-specific and AF-agnostic PROs. We displayed these findings over time (Figure) and conducted a linear regression analysis for each PRO. Results: Of the 3,208 AF clinical trials, 569 (17.7%) reported using at least one PRO, with 178 (5.5%) using AF-specific PROs. There was a statistically significant increase in the use of PROs between 2000 and 2023 (8 vs. 518; P < 0.001; R2= 0.959). This finding held for both AF-specific PROs between 2000 and 2023 (0 vs. 79; P < 0.001; R2=0.930) and AF-agnostic PROs between 2000 and 2023 (8 vs. 360; P < 0.001; R2=0.969). The Atrial Fibrillation Effect on Quality-of-life (AFEQT) was the most used AF-specific PRO, utilized 130 times, with its usage increasing between 2000 and 2023 (0 vs. 61; P = 0.003; R2= 0.888). The EQ-5D was the most frequently used AF-agnostic PRO, employed 131 times. Conclusion: The study reveals a significant increase in the use of PROs in AF clinical trials over time. While most trials use AF-agnostic PROs for measuring QoL, several AF-specific PROs, especially AFEQT, have gained wide adoption. These findings underscore the importance of patient-centred outcomes and suggest the increasing emphasis on PROs in AF research. However, significant heterogeneity remains in the choice of PROs, with limited utilisation of validated, AF-specific measures. Future research should focus on understanding the distinct strengths and limitations of AF-specific PROs compared to AF-agnostic ones and promoting their appropriate integration into AF clinical trials to improve patient-centred care for AF patients.Figure

  • Open Access

    Impact of industry funding on atrial fibrillation clinical trials: insights and implications

    by R Lan, I P Paranjpe, M S Saeed, M V P Perez

    Background/Introduction: Commercial industry is an important source of funding for atrial fibrillation clinical trials, the implications of which have not been analyzed. Purpose: The purpose of this study is to describe the characteristics of contemporary AF clinical trials and to evaluate their association with funding source. Methods: We systematically assessed all completed atrial fibrillation trials registered in ClinicalTrials.gov between conception to September 1, 2022, and extracted publicly available information including funding source, trial size, race, ethnicity, sex, intervention, location, and publication status. Trial characteristics were compared using the Wilcoxon rank sum test and Fisher’s exact test for continuous and categorical variables, respectively. Results: Of the 253 clinical trials assessed, 171 (68%) reported industry funding. Industry funding was associated with a greater median total enrollment (172 vs. 80; P < 0.001), publication rate (56.7% vs. 42.7%; P = 0.04), participation in device trials (48.0% vs. 24.4%; P < 0.001), and multicontinental recruitment location (25.2% vs. 2.4%; P < 0.001) when compared to non-industry funded clinical trials. However, industry funding was not associated with a significant difference in median impact factor (7.7 vs. 7.7; P = 0.723) or median number of citations (60.0 vs. 29.0; P = 0.09). The overall proportion of industry funded trials did not change over time (P = 1.00) since inception of the ClinicalTrials.gov database. Participant demographics remained relatively uniform over time across both industry-funded and non-industry-funded trials. Conclusion(s). Industry funded clinical trials in atrial fibrillation are often larger, more frequently published, multicontinental, and device-focused. Industry funding was found to be associated with significant differences in study enrollment, publication metrics, and study interventions. Insights from this study inform trial design, regulation, and policy considerations in the evolving landscape of AF research.TableFigure

  • Diversity in atrial fibrillation trials: Assessing the role of language proficiency as a recruitment barrier

    by Roy H. Lan, Eduardo Perez Guerrero, Sa Shen, FeiFei Qin, Victor Ritter, Cati Brown-Johnson, Kira Clark, Erin Rose, Eldrin F. Lewis, Paul J. Wang

  • Rising trend in use of patient-reported outcomes in atrial fibrillation clinical trials

    by Roy H. Lan, Eduardo Perez-Guerrero, Mohammad Saeed, Marco V. Perez


  • Open Access

    Who Are We Missing? Reporting of Transgender and Gender‐Expansive Populations in Clinical Trials

    by Eli N. Rice, Roy H. Lan, Julio C. Nunes, Rushil Shah, Kira Clark, Vyjeyanthi S. Periyakoil, Jonathan H. Chen, Bryant Lin, Melvin Echols, Christopher Awad, et al.